Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) EPS (Basic) (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of EPS (Basic) data on record, last reported at -$1.22 in Q3 2025.

  • For Q3 2025, EPS (Basic) rose 75.7% year-over-year to -$1.22; the TTM value through Sep 2025 reached $32.01, up 171.53%, while the annual FY2024 figure was -$11.89, 50.97% up from the prior year.
  • EPS (Basic) reached -$1.22 in Q3 2025 per ZBIO's latest filing, up from -$1.25 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $35.28 in Q4 2024 and bottomed at -$24.26 in Q2 2024.
  • Average EPS (Basic) over 3 years is -$1.59, with a median of -$1.23 recorded in 2025.
  • Peak YoY movement for EPS (Basic): tumbled 307.44% in 2024, then soared 95.53% in 2025.
  • A 3-year view of EPS (Basic) shows it stood at $2.42 in 2023, then surged by 1357.85% to $35.28 in 2024, then crashed by 103.46% to -$1.22 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$1.22 in Q3 2025, -$1.25 in Q2 2025, and -$0.8 in Q1 2025.